
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus …
2021年7月14日 · Chronic graft-versus-host disease (GVHD), a major complication of allogeneic stem-cell transplantation, becomes glucocorticoid-refractory or glucocorticoid-dependent...
Classification systems for chronic graft-versus-host disease
Chronic graft versus host disease (GVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation. Clinically, chronic GVHD is a pleiotropic, multiorgan syndrome involving tissue inflammation and fibrosis that …
Updates in chronic graft-versus-host disease - American …
2021年12月10日 · Chronic graft-versus-host disease (GVHD) is the leading cause of late morbidity and mortality after allogeneic hematopoietic cell transplantation. Symptoms and manifestations of chronic GVHD are heterogeneous and pleomorphic, and there are no standard treatments beyond corticosteroids.
慢性移植物抗宿主病(cGVHD)指异基因造血干细胞移植(allo-HSCT)后 ,受者在重建供者免疫的过程中,来源于供者的淋巴细胞攻击受者脏器产生的临床病理综合征(包括经典型cGVHD和重叠综合征),是移植后主要并发症之一,发生率为30%~70%[1-2]。 cGVHD 发生机制复杂,临床表现多样,个体差异大,病程迁延持久,如不规范诊治,轻则影响患者生活质量,重则影响远期生存。 随着移植技术体系的不断完善,患者对移植后生活质量的诉求越来越高,重视cGVHD 的防治非常重要。 在参考国内 …
HOME | Cgvh
The Harvard/MGH Center on Genomics, Vulnerable Populations, and Health Disparities is dedicated to conducting research on the complex intersections of emerging genomics research and the persistent problem of health disparities in order to fully leverage the potential of genomics research to improve population health and reduce health disparities.
慢性移植物抗宿主病(cGVHD)诊断与治疗中国专家共识(2021年 …
引用本文: 中华医学会血液学分会造血干细胞应用学组, 中国抗癌协会血液病转化委员会. 慢性移植物抗宿主病(cGVHD)诊断与治疗中国专家共识(2021年版) [J] . 中华血液学杂志, 2021, 42 (4) : 265-275. DOI: 10.3760/cma.j.issn.0253-2727.2021.04.001. 版权归中华医学会所有。 未经授权,不得转载、摘编本刊文章,不得使用本刊的版式设计。 除非特别声明,本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。 1 2. 图1. 17 17. 50 51 52. 53 54 55 56 57 58 59 60. 61 …
Measuring therapeutic response in chronic graft-versus-host ... - PubMed
In 2005, the National Institutes of Health (NIH) Chronic Graft-versus-Host Disease (GVHD) Consensus Response Criteria Working Group recommended several measures to document serial evaluations of chronic GVHD organ involvement.
FDA approves ruxolitinib for chronic graft-versus-host disease
On September 22, 2021, the Food and Drug Administration approved ruxolitinib (Jakafi, Incyte Corp.) for chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic...
Steroid-refractory chronic graft-versus-host disease ... - Nature
2021年7月3日 · Chronic graft-versus-host disease (cGVHD) is one of the major causes of late mortality after allogenic hematopoietic stem cell transplantation. Moderate-to-severe cGVHD...
Epidemiology and Treatment of Chronic Graft-versus-Host ... - PubMed
Chronic graft-versus-host disease (cGVHD) is a complication of hematopoietic cell transplantation (HCT). Although the clinical outcomes of cGVHD are well documented, few studies have assessed treatment practices outside of clinical trials.